PMID- 22917779
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20211021
IS  - 1872-8294 (Electronic)
IS  - 0169-409X (Print)
IS  - 0169-409X (Linking)
VI  - 64
IP  - 13
DP  - 2012 Oct
TI  - Interactions of nanomaterials and biological systems: Implications to 
      personalized nanomedicine.
PG  - 1363-84
LID - S0169-409X(12)00238-4 [pii]
LID - 10.1016/j.addr.2012.08.005 [doi]
AB  - The application of nanotechnology to personalized medicine provides an 
      unprecedented opportunity to improve the treatment of many diseases. 
      Nanomaterials offer several advantages as therapeutic and diagnostic tools due to 
      design flexibility, small sizes, large surface-to-volume ratio, and ease of 
      surface modification with multivalent ligands to increase avidity for target 
      molecules. Nanomaterials can be engineered to interact with specific biological 
      components, allowing them to benefit from the insights provided by personalized 
      medicine techniques. To tailor these interactions, a comprehensive knowledge of 
      how nanomaterials interact with biological systems is critical. Herein, we 
      discuss how the interactions of nanomaterials with biological systems can guide 
      their design for diagnostic, imaging and drug delivery purposes. A general 
      overview of nanomaterials under investigation is provided with an emphasis on 
      systems that have reached clinical trials. Finally, considerations for the 
      development of personalized nanomedicines are summarized such as the potential 
      toxicity, scientific and technical challenges in fabricating them, and regulatory 
      and ethical issues raised by the utilization of nanomaterials.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Zhang, Xue-Qing
AU  - Zhang XQ
AD  - Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, 
      Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 
      02115, USA.
FAU - Xu, Xiaoyang
AU  - Xu X
FAU - Bertrand, Nicolas
AU  - Bertrand N
FAU - Pridgen, Eric
AU  - Pridgen E
FAU - Swami, Archana
AU  - Swami A
FAU - Farokhzad, Omid C
AU  - Farokhzad OC
LA  - eng
GR  - HHSN268201000045C/HL/NHLBI NIH HHS/United States
GR  - U54 CA151884/CA/NCI NIH HHS/United States
GR  - 1F32CA168163-01/CA/NCI NIH HHS/United States
GR  - CAPMC/CIHR/Canada
GR  - F32 CA168163/CA/NCI NIH HHS/United States
GR  - CA151884/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120817
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
RN  - 0 (Ligands)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Ligands
MH  - *Nanomedicine
MH  - Nanostructures/*therapeutic use
MH  - *Precision Medicine
MH  - Protein Binding
PMC - PMC3517211
MID - NIHMS401532
EDAT- 2012/08/25 06:00
MHDA- 2013/03/13 06:00
PMCR- 2013/10/01
CRDT- 2012/08/25 06:00
PHST- 2012/06/01 00:00 [received]
PHST- 2012/07/25 00:00 [revised]
PHST- 2012/08/09 00:00 [accepted]
PHST- 2012/08/25 06:00 [entrez]
PHST- 2012/08/25 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - S0169-409X(12)00238-4 [pii]
AID - 10.1016/j.addr.2012.08.005 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2012 Oct;64(13):1363-84. doi: 10.1016/j.addr.2012.08.005. 
      Epub 2012 Aug 17.